Compare AKBA & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | NRC |
|---|---|---|
| Founded | 2007 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 390.8M |
| IPO Year | 2014 | 1997 |
| Metric | AKBA | NRC |
|---|---|---|
| Price | $1.43 | $18.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 62.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.63% |
| EPS Growth | 93.94 | ★ 4707.69 |
| EPS | N/A | ★ 50.00 |
| Revenue | N/A | ★ $119,686,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.35 |
| Revenue Growth | N/A | ★ 1.81 |
| 52 Week Low | $1.14 | $9.76 |
| 52 Week High | $4.08 | $22.79 |
| Indicator | AKBA | NRC |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 61.60 |
| Support Level | $1.30 | $17.85 |
| Resistance Level | $1.55 | $18.18 |
| Average True Range (ATR) | 0.08 | 0.74 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 42.37 | 82.48 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.